- Previous Close
0.0000 - Open
0.0423 - Bid --
- Ask --
- Day's Range
0.0423 - 0.0423 - 52 Week Range
0.0423 - 0.0423 - Volume
10,000 - Avg. Volume
0 - Market Cap (intraday)
1.382M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 1, 2023
- 1y Target Est
--
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.
www.crismtherapeutics.comRecent News: AMMCF
View MorePerformance Overview: AMMCF
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMMCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMMCF
View MoreValuation Measures
Market Cap
3.95M
Enterprise Value
1.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.66%
Return on Equity (ttm)
-62.45%
Revenue (ttm)
-31k
Net Income Avi to Common (ttm)
-1.77M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.42M